Brief: Rallybio Announces Positive Phase 1 Single Ascending Dose Results For Rlyb116

Rallybio

07/11/2022 12:52

Nov 7 (Reuters) - Rallybio Corp  RLYB.O :
    * RALLYBIO ANNOUNCES POSITIVE PHASE 1 SINGLE ASCENDING DOSE
RESULTS FOR RLYB116, AN INNOVATIVE SUBCUTANEOUSLY INJECTED
INHIBITOR OF COMPLEMENT COMPONENT 5
    * RALLYBIO CORP - 100 MG RESULTS DEMONSTRATED A REDUCTION OF
>99%
IN FREE C5 WITH POTENTIAL FOR WEEKLY OR LESS FREQUENT
SELF-ADMINISTERED DOSING
    * RALLYBIO CORP - RLYB116 ADMINISTERED AS A SINGLE 100 MG
DOSE WAS
GENERALLY WELL-TOLERATED
    * RALLYBIO CORP - PHASE 1 MULTIPLE ASCENDING DOSE STUDY
EXPECTED
TO COMMENCE IN 1Q 2023

Source text for Eikon:  ID:nBw9G2JYRa 
Further company coverage:  RLYB.O 
 ((reuters.briefs@thomsonreuters.com;))